These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 33485405)

  • 1. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.
    Zhou Y; Liu Z; Li S; Xu W; Zhang Q; Silva IT; Li C; Wu Y; Jiang Q; Liu Z; Wang Q; Guo Y; Wu J; Gu C; Cai X; Qu D; Mayer CT; Wang X; Jiang S; Ying T; Yuan Z; Xie Y; Wen Y; Lu L; Wang Q
    Cell Rep; 2021 Feb; 34(5):108699. PubMed ID: 33485405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
    Wan J; Xing S; Ding L; Wang Y; Gu C; Wu Y; Rong B; Li C; Wang S; Chen K; He C; Zhu D; Yuan S; Qiu C; Zhao C; Nie L; Gao Z; Jiao J; Zhang X; Wang X; Ying T; Wang H; Xie Y; Lu Y; Xu J; Lan F
    Cell Rep; 2020 Jul; 32(3):107918. PubMed ID: 32668215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
    Lim SA; Gramespacher JA; Pance K; Rettko NJ; Solomon P; Jin J; Lui I; Elledge SK; Liu J; Bracken CJ; Simmons G; Zhou XX; Leung KK; Wells JA
    MAbs; 2021; 13(1):1893426. PubMed ID: 33666135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 14. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.
    Scheid JF; Barnes CO; Eraslan B; Hudak A; Keeffe JR; Cosimi LA; Brown EM; Muecksch F; Weisblum Y; Zhang S; Delorey T; Woolley AE; Ghantous F; Park SM; Phillips D; Tusi B; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Rzasa K; Hatziioanno T; Durney MA; Gu X; Tada T; Landau NR; West AP; Rozenblatt-Rosen O; Seaman MS; Baden LR; Graham DB; Deguine J; Bieniasz PD; Regev A; Hung D; Bjorkman PJ; Xavier RJ
    Cell; 2021 Jun; 184(12):3205-3221.e24. PubMed ID: 34015271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
    Makdasi E; Levy Y; Alcalay R; Noy-Porat T; Zahavy E; Mechaly A; Epstein E; Peretz E; Cohen H; Bar-On L; Chitlaru T; Cohen O; Glinert I; Achdout H; Israely T; Rosenfeld R; Mazor O
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33810465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
    Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S; Hägglöf T; Oliveira TY; Viant C; Hurley A; Hoffmann HH; Millard KG; Kost RG; Cipolla M; Gordon K; Bianchini F; Chen ST; Ramos V; Patel R; Dizon J; Shimeliovich I; Mendoza P; Hartweger H; Nogueira L; Pack M; Horowitz J; Schmidt F; Weisblum Y; Michailidis E; Ashbrook AW; Waltari E; Pak JE; Huey-Tubman KE; Koranda N; Hoffman PR; West AP; Rice CM; Hatziioannou T; Bjorkman PJ; Bieniasz PD; Caskey M; Nussenzweig MC
    Nature; 2020 Aug; 584(7821):437-442. PubMed ID: 32555388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
    J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
    Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
    Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.